– USA, MA – Corindus Vascular Robotics, Inc. (NYSE: CVRS), a leading developer of precision vascular robotics, today announced that James (Jim) Tobin has been appointed to its Board of Directors, effective immediately.
President and Chief Executive Officer Mark Toland stated, “I am pleased to welcome Jim to our board of directors. Jim has had a transformative effect on the healthcare industry. His experience leading key medical companies to tremendous growth and diversification will be incredibly valuable as we continue to accelerate our business.”
Mr. Tobin has served in multiple executive positions over his extensive career, building and executing operational growth strategies for large businesses across the healthcare sector. Mr. Tobin served as Chief Executive Officer for Boston Scientific from March 1999 to July 2009 during which time the company’s revenues grew significantly from more than $2 billion to over $8 billion. Prior to joining Boston Scientific, Mr. Tobin served as President and CEO of Biogen Inc., where he was instrumental in making it one of the world’s most successful biotechnology companies. Before joining Biogen, Mr. Tobin was President and Chief Operating Officer of Baxter International and responsible for all operations of the $9 billion company. Mr. Tobin currently serves on a number of Boards, including TransMedics, Inc., Oxford Immunotec Global PLC, and Globus Medical, Inc. Mr. Tobin holds an A.B. from Harvard College and an M.B.A. from Harvard Business School.
Mr. Tobin said, “I am thrilled to join Corindus, a proven innovator in interventional treatment. I look forward to working with the Corindus team on their mission of advancing vascular robotic technology to further improve patient care.”
About Corindus Vascular Robotics, Inc.
Corindus Vascular Robotics, Inc. is a global technology leader in robotic-assisted vascular interventions. The company’s CorPath® System is the first FDA-cleared medical device to bring robotic precision to percutaneous coronary and percutaneous vascular procedures. During the procedure, the interventional cardiologist sits at a radiation-shielded workstation to advance guide catheters, stents, and guidewires with millimeter-by-millimeter precision. The workstation allows the physician greater control and the freedom from wearing heavy lead protective equipment that causes musculoskeletal injuries. With the CorPath System, Corindus Vascular Robotics brings robotic precision to interventional procedures to help optimize clinical outcomes and minimize the costs associated with complications of improper stent placement during manual procedures. Corindus stands behind its product with its unique $1,000 hospital credit “One Stent Program.”
For more information : http://www.corindus.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
Comments are closed.